Company facts
- Industry
- Hospital & Medical Service Plans
- Headquarters
- Bloomfield, Connecticut
- Most recent report
- 10-Q, filed Nov 5, 2026
- Incorporated
- Delaware
- Filings on record
- 1,002+ filings
- On EDGAR
- CIK 1739940
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 32
News 8 of 135
- 8-K Quarterly results Nov 5, 2026
- 8-K Leadership change Oct 9, 2026
- 8-K Current report on a material event Sep 30, 2026
- 8-K Quarterly results Jul 30, 2026
- 8-K Current report on a material event May 13, 2026
- 8-K Quarterly results Apr 30, 2026
- 8-K Shareholder vote results Apr 27, 2026
- 8-K Leadership change Mar 3, 2026
Prospectuses and Registrations 8 of 24
- 424B5 Prospectus supplement for an offering Sep 4, 2025
- FWP Free writing prospectus Sep 3, 2025
- 424B5 Prospectus supplement for an offering Sep 2, 2025
- S-3ASR Automatic shelf registration Sep 2, 2025
- 424B5 Prospectus supplement for an offering Feb 7, 2024
- FWP Free writing prospectus Feb 6, 2024
- 424B3 Prospectus supplement for an offering Feb 5, 2024
- 424B5 Prospectus supplement for an offering Mar 2, 2023
Proxies 8 of 35
- DEFA14A Extra proxy material Mar 13, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 13, 2026
- DEFA14A Extra proxy material Mar 14, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 14, 2025
- DEFA14A Extra proxy material Apr 12, 2024
- PX14A6G Shareholder's own proxy material Apr 11, 2024
- DEFA14A Extra proxy material Apr 5, 2024
- DEFA14A Extra proxy material Mar 15, 2024
Ownership 8 of 750
- 4 Insider reported a trade Sep 8, 2026
- 4 Insider reported a trade Sep 3, 2026
- 144 Notice of a proposed sale of restricted stock Sep 3, 2026
- 4 Insider reported a trade Sep 2, 2026
- 4 Insider reported a trade Aug 20, 2026
- 4 Insider reported a trade Aug 20, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
- 4 Insider reported a trade Aug 6, 2026
Other 8 of 26
- 11-K Employee stock plan report Jun 24, 2026
- ARS Annual report sent to shareholders Mar 13, 2026
- 11-K Employee stock plan report Jun 27, 2025
- ARS Annual report sent to shareholders Mar 14, 2025
- UPLOAD Comment letter from SEC staff Jan 29, 2025
- CORRESP Reply to SEC staff Jan 16, 2025
- UPLOAD Comment letter from SEC staff Dec 20, 2024
- CORRESP Reply to SEC staff Nov 21, 2024
What to read: Sep 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 1 positive, 9 notable, and 2 negative flags.
Financial Statements (Item 1)
Financial statements and notes with material balance-sheet swings, debt changes, and segment detail.Notable- Accounts receivable factoring facilities sold $2.0B in receivables YTD 2026, down from $4.0B in 2025.
- Supplier finance program had $1.4B confirmed as valid at Sep 2026, predominantly with one supplier.
- Strategic optimization program cost $535M pre-tax YTD 2026 ($405M after-tax), with $431M in severance charges.
Management's Discussion (Item 2)
Segment results diverge sharply: Evernorth profit fell while Cigna Healthcare surged. Cash flow dropped.Notable- Company announced Accelerate to One initiative at September 2026 Investor Day, a multi-year modernization program.
- Company announced planned exit from Individual and Family Plans medical business as of January 1, 2027.
- Cigna Healthcare MCR rose 20 bps to 85.0% in Q3, driven by U.S. Employer business (+80 bps).
- Cigna Healthcare medical customers grew 2% to 18.45M, but U.S. Healthcare insured customers fell 6% to 2.41M.
- Debt-to-capitalization ratio improved to 41.8% from 43.0% at year-end 2025.
- Share repurchases collapsed to $500M in 9M 2026 from $2.6B in 9M 2025, a 81% drop.
What changed: Sep 2026 vs. Jun 2026
About 4% of CI's Sep 2026 10-Q is new information. 11 paragraphs were added, 130 changed, and 13 removed. Below are the most important lines SECSift identified.
Changed
- Adjusted income from operations rose to $2,104M for Q3 2026 from $2,096M in Q3 2025.
- Cigna Healthcare pre-tax adjusted income rose 15% to $1,193M for Q3 2026 from $1,038M in Q3 2025.
- Evernorth pre-tax adjusted income fell 4% to $1,829M for Q3 2026 from $1,903M in Q3 2025.
- Shareholders' net income fell 23% to $1,442M for Q3 2026 from $1,868M in Q3 2025.
- Employees tendered 2,435 shares in September 2026, down from 10,003 in June 2026.
- Exhibit 101 now references quarter ended September 30, 2026, changed from June 30, 2026.
Everything here comes from Cigna Group's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 5, 2026, from the 10-Q for Sep 2026.